Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4349809 | 0.93 | SMN1; SMN2 (0.43) | SLC6A2SLC6A4SLC6A3SMN1; SMN2MAPK1 | |
| SCHEMBL6671731 | 0.91 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3SMN1; SMN2SLC6A9 | |
| SCHEMBL4351160 | 0.89 | SLC6A4 (0.43) | SLC6A4SMN1; SMN2MAPK1L3MBTL1POLB | |
| SCHEMBL4353891 | 0.89 | SMN1; SMN2 (0.39) | SLC6A2SLC6A4SLC6A3SMN1; SMN2MAPK1 | |
| SCHEMBL4354316 | 0.88 | BLM (0.38) | SLC6A2SLC6A4SLC6A3SMN1; SMN2MAPK1 | |
| SCHEMBL4343735 | 0.86 | ITGB2 (0.39) | SMN1; SMN2MAPK1USP7CXCR2 | |
| SCHEMBL4360001 | 0.85 | POLB (0.50) | SMN1; SMN2L3MBTL1TP53POLBRXFP1 | |
| SCHEMBL4351799 | 0.85 | LMNA (0.40) | SMN1; SMN2SLC6A9L3MBTL1POLBRXFP1 | |
| SCHEMBL6671733 | 0.85 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL4348905 | 0.85 | SLC6A4 (0.50) | SLC6A2SLC6A4SLC6A3SMN1; SMN2SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | JERINI AG (DE) | 2011-03-17 | — | — | US | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | claimed |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | JERINI AG (DE) | 2007-03-08 | — | — | US | claimed |
| CN-1701061-A | Novel compounds for inhibiting rotamase enzymes and uses thereof | JERINI AG (DE) | 2005-11-23 | — | — | CN | claimed |
| EP-1539683-A2 | PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS | Jerini AG (DE) | 2005-06-15 | — | — | EP | claimed |
| WO-2004026815-A2 | PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS | JERINI AG (DE) | 2004-04-01 | — | — | WO | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | NR1I3, NR1D1, NR1D2 | SLC6A2 2386/4885SLC6A4 1100/4885SLC6A3 1867/4885 |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | NR1I3, NR1D1, NR1D2 | SLC6A2 2323/4885SLC6A4 1325/4885SLC6A3 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.